Ph3 Study of Sonrotoclax plus Zanubrutinib in patients with Mantle Cell Lymphoma
Phase III Clinical Trial
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients WithRelapsed/Refractory Mantle Cell Lymphoma(BGB-11417-302)